Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late
JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)...
Source: globenewswire.com